- Home
- TGTX vs NXE Comparison
TGTX vs NXE Comparison
Compare TGTX & NXE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- NXE
- Stock Information
- Founded
- TGTX 1993
- NXE 2011
- Country
- TGTX United States
- NXE Canada
- Employees
- TGTX N/A
- NXE N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- NXE
- Sector
- TGTX Health Care
- NXE
- Exchange
- TGTX Nasdaq
- NXE Nasdaq
- Market Cap
- TGTX 5.1B
- NXE 5.0B
- IPO Year
- TGTX 1995
- NXE N/A
- Fundamental
- Price
- TGTX $36.73
- NXE $8.83
- Analyst Decision
- TGTX Strong Buy
- NXE
- Analyst Count
- TGTX 6
- NXE 0
- Target Price
- TGTX $47.50
- NXE N/A
- AVG Volume (30 Days)
- TGTX 1.9M
- NXE 9.5M
- Earning Date
- TGTX 11-03-2025
- NXE 11-07-2025
- Dividend Yield
- TGTX N/A
- NXE N/A
- EPS Growth
- TGTX N/A
- NXE N/A
- EPS
- TGTX 0.36
- NXE N/A
- Revenue
- TGTX $454,069,000.00
- NXE N/A
- Revenue This Year
- TGTX $82.22
- NXE N/A
- Revenue Next Year
- TGTX $47.76
- NXE N/A
- P/E Ratio
- TGTX $101.18
- NXE N/A
- Revenue Growth
- TGTX 30.96
- NXE N/A
- 52 Week Low
- TGTX $21.16
- NXE $3.91
- 52 Week High
- TGTX $46.48
- NXE $9.43
- Technical
- Relative Strength Index (RSI)
- TGTX 72.14
- NXE 57.51
- Support Level
- TGTX $34.52
- NXE $8.57
- Resistance Level
- TGTX $37.45
- NXE $9.18
- Average True Range (ATR)
- TGTX 1.10
- NXE 0.45
- MACD
- TGTX 0.59
- NXE -0.05
- Stochastic Oscillator
- TGTX 90.30
- NXE 52.21
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About NXE Nexgen Energy Ltd.
NexGen Energy Ltd is an exploration and development entity engaged in acquiring, evaluating, and developing uranium properties in Canada. The company's projects portfolio consists of ROOK I, and the IsoEnergy, at the Athabasca Basin.